
Bortezomib (Velcade) in combination with dexamethasone or pegylated liposomal doxorubicin for relapsed multiple myeloma

NIHR HSC

Record Status

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

NIHR HSC. Bortezomib (Velcade) in combination with dexamethasone or pegylated liposomal doxorubicin for relapsed multiple myeloma. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012

Final publication URL

<http://www.hsc.nihr.ac.uk/topics/bortezomib-velcade-in-combination-with-dexamethaso/>

Indexing Status

Subject indexing assigned by CRD

MeSH

Dexamethasone; Multiple Myelomas; Boronic Acids; Pyrazines; Polyethylene Glycols; Doxorubicin; Antineoplastic Combined Chemotherapy Protocols

Language Published

English

Country of organisation

England

English summary

An English language summary is available.

Address for correspondence

The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269 Email: c.packer@bham.ac.uk

AccessionNumber

32012000821

Date abstract record published

15/11/2012